Research Leadership
The Kidney Cancer Research Consortium brings together some of the nation’s best researchers in clinical kidney cancer trials, enabling multi-site studies at a greatly reduced cost.
The collaborative nature of the Consortium also improves trial enrollment numbers and access to underserved populations of patients. The KCRC includes some of the highest volume renal cell carcinoma clinical trial sites in the country.
Clinical Trial Leadership
The Consortium sites are led by veteran researchers with over 100 years of combined experience. KCRC investigators are nationally and internationally renowned for their work and heralded as thought leaders around the globe.
What We Offer
KCRC researchers are leaders in clinical trial study design and kidney cancer treatment development. Collaboration between experienced researchers across multiple sites enables innovative study at a fraction of the cost of a traditional CRO.
Information for Patients
Patients with kidney cancer may benefit from participation in clinical trials at any point in their treatment. Read on for more information and to locate enrolling trials.
Research News
Kidney cancer research is a rapidly-advancing area of oncology. Read about the latest research coming from Consortium sites and others researching treatment for RCC.
The Kidney Cancer Research Consortium Members
The Consortium members have over 100 years of combined experience in kidney cancer clinical research. KCRC brings an unmatched commitment to and expertise to RCC trials.
Eric Jonasch, M.D.
Dr. Jonasch leads the Consortium. He is a professor in the Department of GU Medical Oncology, Division of Cancer Medicine, at the University of Texas MD Anderson Cancer Center. Dr. Jonasch's research focuses on clear-cell RCC and VHL with an interest in replication stress and microenvironmental determinants of resistance to therapy.
Hans Hammers, M.D., Ph.D.
Dr. Hammers is a nationally and internationally recognized medical oncologist focusing primarily on kidney cancer. Dr. Hammers is an international thought leader in immunotherapy, a form of treatment that boosts the body’s own immune defenses to help fight cancer – and one that is changing the kidney cancer landscape.
Brian Rini, M.D.
Dr. Rini is an internationally recognized leader in genitourinary oncology, kidney cancer, and clinical drug development. He is an Ingram Professor of Medicine at Vanderbilt University in the deperatments of hematology and oncology, where he leads kidney cancer clinical research efforts, and also serves as the Chief of Clinical Trials.
Naomi Haas, M.D.
Dr. Haas is an international expert in the conduct and design of adjuvant clinical trials for kidney cancer, as well as a national expert in prostate and kidney cancer therapeutics. She is the director of the Prostate and Kidney Cancer Program at UPenn, as well as co-leader of the Cancer Therapeutics Program at Abramson Cancer Center.
Daniel George, M.D.
Dr. George oversees a large clinical research team at Duke focused on developing therapy and improving care and outcomes for patients with urologic cancers. His work involves both interventional trials with new and emerging therapies, as well as diagnostic tests and markers of cancer biology, response, and outcome.
David McDermott, M.D.
Dr. McDermott is a professor of medicine at Harvard, as well as the co-leader of the Kidney Cancer program at Dana-Farber/HCC. He focuses on identifying meaningful biomarkers for early detection and prognosis, underlying mechanisms of disease biology, and novel therapeutic targets for various kidney cancer populations.
Ulka Vaishampayan, M.D., Ph.D.
Dr. Vaishampayan is the Director of the Phase I program at the Rogel Cancer Center, University of Michigan, Ann Arbor MI. Dr. Vaishampayan is a Professor of Internal Medicine and her research is primarily in translational drug development and early phase clinical trials in cancer with a focus on genitourinary malignancies.
The Latest Tweets from Consortium Investigators:
; Y’all, @JVentoMD knocked this #RCC tweetorial out of the park ⬇️⬇️! Definitely want to take a look if you want an easy to follow thread with 💯 use of emojis
@HemOncFellows @TumorBoardTues @brian_rini @Uromigos https://twitter.com/jventomd/status/1635792959328100352
@TumorBoardTues 1/17 #TumorBoardTuesday #RenalCancer #OncTwitter
68yo👨🏾
HTN
T2DM
Arthritis
✂️2022: L Radical Nephrectomy
🔬Clear cell #RenalCellCarcinoma
📏8.2 cm, Grade 2, extends into renal vein (T3a)
❓No lymph nodes sampled (NX)
❌No other dz sites
What would you pick for adj therapy?
@SuyogCancer @TumorBoardTues @brian_rini @montypal @PGrivasMDPhD @rafee_talukder @shilpaonc @DrYukselUrun @TiansterZhang @KidneyCancer @HHammersMD @arihakimi @RCCadvocate @QingZhangLab @DrRanaMcKay @DrScottHaake @MVossMD @archie_hh @DrTanWP @mtsiatas @sonpavde I've attached the subgroup analysis from the 3 published trials (awaiting PROSPER publication). Can see breakdown by stage, Checkmate 914 did not include M1 with NED but other 3 did.
Possibly. The M1 group was fairly unique in KEYNOTE. I agree the HR is compelling but I do worry that one year of monotherapy is not enough.
@JVentoMD @SuyogCancer @TumorBoardTues @brian_rini @montypal @PGrivasMDPhD @rafee_talukder @shilpaonc @DrYukselUrun @TiansterZhang @KidneyCancer @HHammersMD @arihakimi @RCCadvocate @QingZhangLab @DrRanaMcKay @DrScottHaake @MVossMD @archie_hh @DrTanWP @sonpavde Do you consider 1-year “adjuvant” pembro for M1 NED patients as “undertreatment”???
@TumorBoardTues @brian_rini @montypal @PGrivasMDPhD @rafee_talukder @shilpaonc @DrYukselUrun @TiansterZhang @KidneyCancer @HHammersMD @arihakimi @RCCadvocate @QingZhangLab @DrRanaMcKay @DrScottHaake @MVossMD @archie_hh @DrTanWP @mtsiatas @sonpavde 16/17 #TumorBoardTuesday
👍Pros of adj pembro: improved DFS 🕺 in similar pts with high relapse risk
👎Cons: ≈ ⅓ pts with ≥ g3 tox, time 🕑+💰tox
🤔This patient started tx before CheckMate 914, IMmotion010, PROSPER results
❓How to discuss the results with similar patients❓
@JVentoMD @TumorBoardTues @brian_rini @montypal @PGrivasMDPhD @rafee_talukder @shilpaonc @DrYukselUrun @TiansterZhang @KidneyCancer @HHammersMD @arihakimi @RCCadvocate @QingZhangLab @DrRanaMcKay @DrScottHaake @MVossMD @archie_hh @DrTanWP @mtsiatas @sonpavde Is DFS the right endpoint?
#TumorBoardTuesday
https://pubmed.ncbi.nlm.nih.gov/36639103/
@TumorBoardTues @brian_rini @montypal @PGrivasMDPhD @rafee_talukder @shilpaonc @DrYukselUrun @TiansterZhang @KidneyCancer @HHammersMD @arihakimi @RCCadvocate @QingZhangLab @DrRanaMcKay @DrScottHaake @MVossMD @archie_hh @DrTanWP @mtsiatas @sonpavde 14/17 #TumorBoardTuesday
Back to our case🔎
68yo 👨🏾
HTN
T2DM
Arthritis
✂️2022: L Radical Nephrectomy
🔬Clear cell #RenalCellCarcinoma
📏8.2 cm, G2, extends into renal vein (T3a)
❓No lymph nodes sampled (NX)
🦴No other dz sites
🤔Now knowing data, would you offer adjuvant IO?